Familial Amyloid Polyneuropathy Therapeutics Market Size, Share & Industry Analysis By Drug Type (Inotersen, Tafamidis, Patisiran, Others), By Disease Type (Familial Amyloid Polyneuropathy-I (FAP-I), Familial Amyloid Polyneuropathy-II (FAP-II), Familial Amyloid Polyneuropathy-III (FAP-III), Familial Amyloid Polyneuropathy-IV (FAP-IV)), By Gender Type (Male, Female), By Distribution Channel (Hospital Pharmacies, Retail pharmacies, Online Pharmacies) Others and Regional Forecast, 2024-2032

Familial amyloid polyneuropathy (FAP) or transthyretin (TTR) amyloid polyneuropathy, is an inherited, progressive and a rare disease caused by the unusual deposits of amyloids or proteins around peripheral nerves and other tissues. FAP is considered to be very rare in most countries of the world. The incidence rate of the disease is estimated to be comapratively lower in developed countries such as the U.S. and several other European countries. In other regions of the world, the prevalence is comparatively higher.

The familial amyloid polyneuropathy therapeutics market is estimated to witness substantial growth across the forecast period. High growth is attributable to increasing number of therapeutic drugs being approved for the treatment of the disease. Moreover, rising incidence of familial amyloid polyneuropathy disorder across various countries of the world is another major factor augmenting market growth. Additionally, increasing adoption rate of therapeutic drugs for treatment of the disease, owing to rising awarness among the population of emerging countries such as India, China and others will create new opportunities for the familial amyloid polyneuropathy market. Also, increasing number of companies operating in the market will further provide lucrative growth opportunities. Hence, the aforementioned factors will reflect a positive growth trajectory for the familial amyloid polyneuropathy therapeutics market across the forecast period.

However, high cost associated with the research & development and treatment activities might restrict market growth up to a certain extent. Also, stringent government norms related to approval of such drugs is another chief factor limiting market growth.

Market Segmentation:

By drug type, the market is segmented into inotersen, tafamidis, patisiran and others. Based on disease type, the market is segmented into Familial Amyloid Polyneuropathy-I (FAP-I), Familial Amyloid Polyneuropathy-II (FAP-II), Familial Amyloid Polyneuropathy-III (FAP-III) and Familial Amyloid Polyneuropathy-IV (FAP-IV). Based on gender type, the familial amyloid polyneuropathy therapeutics market is bifurcated into male and female. Furthermore, the distribution channel is classified as hospital pharmacies, retail pharmacies and online pharmacies.

From a geographical standpoint, the market is categorized into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa.

Key Players Covered:

The major companies in the global familial amyloid polyneuropathy therapeutics market report includes Pfizer Inc., Alnylam Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., Corino Therapeutics Inc., Proclara Biosciences, Arcturus Therapeutics Inc., and others.   

Key Insights

• Product Pipeline of the Therapeutic Drugs for Familial Amyloid Polyneuropathy


• Prevalence Ratio of Familial Amyloid Polyneuropathy, Key Countries, 2018


• New Product Launch, Key Players  


• Product Approvals and Clinical Trial stage Data

Regional Analysis:

The global familial amyloid polyneuropathy therapeutics market has been segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa. Asia Pacific region is estimated to witness lucrative growth across the forecast period. High growth is attributed to increasing prevalence of familial amyloid polyneuropathy disorder across various countries of the Asia Pacific regions. North America, followed by Europe is expected to hold substantial amount of shares across 2018 to 2026, owing to growing number of market players operating in the regions.

Moreover, Latin America and Middle East & Africa are projected to register a comparatively higher CAGR by the end of the forecast period, due to growing awareness among the population about the various benefits associated with familial amyloid polyneuropathy therapeutics, coupled with growing adoption rate of the drugs in these countries.

Segmentation

 Familial Amyloid Polyneuropathy Therapeutics Industry Developments

• In July 2019, Alnylam Pharmaceuticals Inc., announced the Health Canada approval and immediate availability of ONPATTRO (patisiran) for the treatment of polyneuropathy in adult patients with hereditary transthyretin-mediated (hATTR) amyloidosis. Such approvals allow the company to cover untapped markets, thus augmenting revenue growth.


• In August 2017, Pfizer Inc. announced the successful analysis results of long-term data from four studies indicating that treatment with tafamidis is associated with delay in disease progression in patients with hereditary amyloid polyneuropathy and was well tolerated, with no unexpected side effects. Such approvals enabled the company to generate more revenue.